For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Files New Dosage Forms for XBB.1.5 COVID Vaccine
October 2, 2023
- Medipal/JCR to Pair Up for Mucopolysaccharidosis Type IIIB Drug
September 29, 2023
- Eisai/Tokio Marine Launch Dementia Insurance Ahead of Leqembi Rollout
September 29, 2023
- Acoalan Misses Mark in PIII Preeclampsia Trial: Kyowa Kirin
September 29, 2023
- Pioneer Director Atsushi Kitamura Picked as Astellas CFO
September 29, 2023
- Entyvio Subcutaneous Form Approved in US: Takeda
September 29, 2023
- Shionogi’s Fragile X Syndrome Drug Gets Rare Pediatric Disease Tag in US
September 29, 2023
- Lilly Japan to Build New Manufacturing Facility, Eyes Mounjaro Supply Boost
September 28, 2023
- Mundipharma Files Anesthetic Med Anerem for New Indication in Japan
September 28, 2023
- Sawai’s Revlimid Generic Gets MDS Nod; December Listing Eyed
September 28, 2023
- Lucentis, Rituxan Biosimilars Win Label Expansions
September 28, 2023
- Pfizer Rolls Out Alopecia Areata Drug Litfulo in Japan
September 28, 2023
- Ono, Adimab Join Hands to Discover Antibody Drugs for Cancer
September 28, 2023
- Regeneron to Make Japan Debut with Dupixent Copromotion
September 27, 2023
- Lilly’s Alzheimer’s Therapy Filed in Japan, Approval Eyed in 2024
September 27, 2023
- LEO Pharma’s Eczema Drug Adtralza Now Available in Japan
September 27, 2023
- CureApp’s Hypertension Therapeutic App Shows Effects in Clinical Setting
September 27, 2023
- Viatris Japan to Go After Drugs in All Phases of Life Cycle, Group Consolidation by Year-End: Chief
September 26, 2023
- Oncolys, Cornell University to Partner in IIT of Telomelysin Combo
September 26, 2023
- Takeda Files Low-Dose Form of Ninlaro in Japan
September 25, 2023
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…